{"product_id":"south-america-ecmo-market-forecast-to-2028-covid-19-impact-and-regional-analysis-by-modality-venoarterial-ecmo-venovenous-ecmo-and-arteriovenous-ecmo-application-respiratory-and-cardiology-and-age-group-adults-pediatrics-and-neonates","title":"South America ECMO Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)","description":"\u003cp\u003eSouth America ECMO Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)\u003c\/p\u003e \n\n\u003cp\u003eThe South America ECMO market is expected to grow from US$ 53.00 million in 2022 to US$ 60.58 million by 2028. It is estimated to record a CAGR of 2.3% from 2022 to 2028.\u003c\/p\u003e \n\n\u003cp\u003eGrowing Adoption of ECMO in Lung Transplantation Procedures Bolsters South America ECMO Market Growth\u003c\/p\u003e \n\n\u003cp\u003eLung transplantation is a life-saving treatment option for patients suffering from end-stage lung diseases, such as COPD, Idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, to improve the quality of life. ECMO is a versatile tool used in all lung transplantation phases, such as preoperative, intraoperative, and postoperative periods. It acts as a bridge in patient undergoing lung transplantation. Therefore, the adoption of ECMO during lung transplantation is growing rapidly to manage patients with life-threatening lung disease. Primary graft dysfunction (PGD) is the leading cause of death after a lung transplant. Thus, ECMO is used penultimately in treating PGD post lung transplantation. Thus, the demand for ECMO equipment is growing for treating the patients suffering from PGD.\u003c\/p\u003e \n\n\u003cp\u003eSouth America ECMO Market Overview\u003c\/p\u003e \n\n\u003cp\u003eThe SAM ECMO market is segmented into Brazil, Argentina, and the Rest of SAM. Brazil dominated the market in 2022. According to World Heart Federation, noncommunicable diseases such as cardiovascular disease accounts for 74% of total deaths in Brazil. According to Global Burden Study (GBD) and Brazilian Unified Health System, cardiovascular disease was the leading cause of death in Brazil in 2019. Due to the increasing aging population in Brazil, the prevalence of cardiovascular diseases is increasing each year. According to GBD, the number of ischemic heart disease (IHD) cases reached 4 million in 2019. Further, about 171,246 deaths were reported due to IHD, which accounted for 43% of cardiovascular deaths and 12% of total deaths in Brazil in 2019. Thus, growing cardiovascular disease cases in Brazil are driving the ECMO market growth in the country.\u003c\/p\u003e \n\n\u003cp\u003eSouth America ECMO Market Revenue and Forecast to 2028 (US$ Million)\u003c\/p\u003e \n\n\u003cp\u003eSouth America ECMO Market Segmentation\u003c\/p\u003e \n\n\u003cp\u003eThe South America ECMO market is segmented based on modality, application, age group, and country.\u003c\/p\u003e \n\n\u003cp\u003eBased on modality, the SAM ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held the largest market share in 2022.\u003c\/p\u003e \n\n\u003cp\u003eBased on application, the SAM ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held a larger market share in 2022.\u003c\/p\u003e \n\n\u003cp\u003eBased on age group, the SAM ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held the largest market share in 2022.\u003c\/p\u003e \n\n\u003cp\u003eBased on country, the SAM ECMO market has been categorized into Brazil, Argentina, and the Rest of SAM. Our regional analysis states that Brazil dominated the market in 2022.\u003c\/p\u003e \n\n\u003cp\u003eABIOMED Inc, Braile Biomedica, Fresenius Medical Care AG \u0026amp; Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group are the leading companies operating in the SAM ECMO market.\u003c\/p\u003e\n\n\u003cp\u003eReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eSave and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM ECMO market. \u003cbr\u003e\nHighlights key business priorities in order to assist companies to realign their business strategies \u003cbr\u003e\nThe key findings and recommendations highlight crucial progressive industry trends in the SAM ECMO market, thereby allowing players across the value chain to develop effective long-term strategies \u003cbr\u003e\nDevelop\/modify business expansion plans by using substantial growth offering developed and emerging markets \u003cbr\u003e\nScrutinize in-depth SAM market trends and outlook coupled with the factors driving the ECMO market, as well as those hindering it \u003cbr\u003e\nEnhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 112 Pages \/ MCW16239811","offer_id":47656907604274,"sku":null,"price":3600.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/south-america-ecmo-market-forecast-to-2028-covid-19-impact-and-regional-analysis-by-modality-venoarterial-ecmo-venovenous-ecmo-and-arteriovenous-ecmo-application-respiratory-and-cardiology-and-age-group-adults-pediatrics-and-neonates","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}